Arca
Skip to content
Tools
Tools

Esophageal cancer

Drug research and approvals for esophageal cancer: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 547 studies of esophageal cancer are recruiting on ClinicalTrials.gov, Health Canada has authorized 12 drug trials for it since 2013, and FDA has 10 approved and 22 open orphan designations naming it.

  • Recruiting worldwide: 547
  • Trials authorized in Canada: 12
  • FDA orphan approvals: 10
  • EU medicines: 0

Recruiting now

Newest posted first, of 547 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 1

Phase 3 12 of 44

Phase 2 12 of 73

  • GefitinibEpidermal growth factor receptor erbB1 inhibitor
  • CadonilimabProgrammed cell death protein 1 inhibitor
  • AfatinibEpidermal growth factor receptor erbB1 inhibitor
  • CatequentinibVascular endothelial growth factor receptor 2 inhibitor
  • CelecoxibCyclooxygenase-2 inhibitor
  • BevacizumabVascular endothelial growth factor A inhibitor
  • PanitumumabEpidermal growth factor receptor erbB1 inhibitor
  • GemcitabineRibonucleoside-diphosphate reductase RR1 inhibitor
  • Hpph
  • HydroxyureaRibonucleoside-diphosphate reductase RR1 inhibitor
  • SunitinibMacrophage colony stimulating factor receptor inhibitor
  • PemetrexedThymidylate synthase inhibitor

Phase 1 or earlier 12 of 42

How its trials ended

1,412 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 277 whose ending is known, 30% met their primary endpoint, 10% missed it and 60% stopped early.

  • Ongoing42430%
  • Completed, result not reported42030%
  • Status unknown29121%
  • Met its primary endpoint846%
  • Stopped: other or unclear765%
  • Stopped: enrollment or feasibility514%
  • Missed its primary endpoint272%
  • Stopped: sponsor or business decision191%
  • Stopped: lack of efficacy101%
  • Stopped: funding6<1%
  • Stopped: safety4<1%

Trials authorized in Canada

The 10 newest of 12; search them all in Canada trials
Dec 18, 2025Rosetta gastric-204: a blinded, randomized, phase 2/3 study of pumitamig in combination with chemotherapy versus nivolumab in combination with chemotherapy in…Pumitamig (BMS-986545; BNT327) / Opdivo [nivolumab (BMS-936558)] / Calcium…Bristol-Myers SquibbOngoing
Sep 19, 2025A phase III, multicentre, randomised controlled study of sonesitatug vedotin in combination with fluoropyrimidine with or without rilvegostomig in first-line…Sonesitatug vedotin (AZD0901) / Rilvegostomig (AZD2936)AstraZeneca PharmaceuticalsOngoing
Oct 25, 2024A phase 2 randomized study to evaluate the safety, efficacy, and optimal dose of ABBV-400 in combination with fluorouracil, leucovorin, and budigalimab as…Telisotuzumab adizutecan (ABBV-400) / Budigalimab (ABBV-181) / Fluorouracil /…AbbVieOngoing
Oct 20, 2022A randomized, open-label, multicenter phase 3 trial of domvanalimab, zimberelimab, and chemotherapy versus nivolumab and chemotherapy in participants with…Zimberelimab (AB122) / Domvanalimab (AB154) / Oxaliplatin / Leucovorin /…Arcus BiosciencesClosed
May 19, 2022A phase I study of organ-preserving endoscopic resection & adjuvant radioimmuno-chemotherapy for esophageal cancer (opera radio)ImfinziUniversity of ManitobaOngoing
Nov 16, 2021Pioneering pre- and post-operative integrative care to improve thoracic cancer quality of care: the thoracic peri-operative integrative surgical care…Vitamin DOttawa Hospital Research InstituteOngoing
Oct 8, 2021A phase 3, randomized study to evaluate the efficacy and safety of pembrolizumab (MK-3475) + lenvatinib (E7080/MK-7902) + chemotherapy compared with standard…MK-7902 (E7080/lenvatinib) / MK-3475 (pembrolizumab)Merck & Co. (MSD)Closed
Aug 12, 2021A randomized trial comparing early local chemoradiation therapy +/- surgery versus systemic therapy for patients with esophageal or gastric cancer with…FluorouracilResearch Institute of The McGill University Health CentreOngoing
Feb 11, 2020A randomized, double-blind, placebo-controlled phase 3 trial of pembrolizumab (MK-3475) versus placebo in participants with esophageal carcinoma receiving…Keytruda (pembrolizumab)Merck & Co. (MSD)Closed
May 26, 2017A randomized, double-blind, placebo-controlled phase III clinical trial of pembrolizumab (MK-3475) in combination with cisplatin and 5-fluorouracil versus…Keytruda / Cisplatin / FluorouracilMerck & Co. (MSD)Ongoing

FDA orphan designations

Approved first, then open designations, newest first; 15 of 32
Aug 25, 2026Ziihera(1) in combination with fluoropyrimidine- and platinum-containing chemotherapy and tislelizumab-jsgr, for the first-line treatment of adult…Jazz Pharmaceuticals Ireland LimitedApproved
Aug 25, 2026TevimbraIn combination with zanidatamab-hrii and fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment for adults…BeOne Medicines USA, Inc.Approved
Mar 3, 2025TevimbraIn combination with platinum-containing chemotherapy, for the first-line treatment of adults with unresectable or metastatic esophageal…BeOne Medicines USA, Inc.Approved
Mar 13, 2024TevimbraAs a single agent, for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma after prior…BeOne Medicines USA, Inc.Approved
May 27, 2022OpdivoIn combination with ipilimumab, for the first-line treatment of adult patients with unresectable advanced or metastatic esophageal squamous…Bristol-Myers Squibb CompanyApproved
May 27, 2022OpdivoIn combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adult patients with…Bristol-Myers Squibb CompanyApproved
May 20, 2021OpdivoAdjuvant treatment of completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease in patients who…Bristol-Myers Squibb CompanyApproved
Apr 16, 2021OpdivoIn combination with fluoropyrimidine- and platinum-containing chemotherapy for the treatment of patients with advanced or metastatic…Bristol-Myers Squibb CompanyApproved
Jun 10, 2020OpdivoOpdivo (nivolumab) indicated for the treatment of patients with unresectable advanced, recurrent or metastatic esophageal squamous cell…Bristol-Myers Squibb CompanyApproved
Dec 27, 1995PhotofrinPhotodynamic therapy with PHOTOFRIN for the palliation of patients with completely obstructing esophageal cancer, or of patients with…QLT Phototherapeutics, Inc.Approved
Aug 30, 2026Sonesitatug vedotinTreatment of esophageal cancerAstraZeneca Pharmaceuticals LPDesignated
Jan 15, 2026Ifinatamab deruxtecanTreatment of esophageal cancerDaiichi Sankyo, Inc.Designated
May 22, 2025Fibroblast activation protein inhibitor radiolabeled with…Diagnostic for the management of esophageal cancerSOFIE Co. dba SOFIEDesignated
Apr 25, 2025Nectin-4-targeting polypeptide conjugated to MMAETreatment of esophageal cancerConjuStar (Zhuhai) Biologics Co., Ltd.Designated
Nov 14, 2024LenvatinibTreatment of esophageal cancerEisai Inc.Designated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.